Trial ID or NCT#

NCT03091660

Status

NOT RECRUITING

Purpose

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.

Official Title

S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Eila C. Skinner
Urologic oncologist, Urologist
Thomas A. Stamey Research Professor in Urology
Harcharan Gill
Urologic oncologist, Urologist, Genitourinary specialist
Kathryn Simmons Stamey Professor
Benjamin I. Chung
Urologic oncologist, Urologic specialist, Urologist, Genitourinary specialist
Associate Professor of Urology at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061